Grace Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Grace Therapeutics, Inc. (GRCE) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $105.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- Grace Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $105.00K, a 65.23% decline year-over-year.
- Grace Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $108.00K, a 32.50% decline year-over-year.
- Grace Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $206.00K, a 1.98% increase year-over-year.
- Grace Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $302.00K, a 26.89% increase year-over-year.
- Grace Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2026 was $798.00K, a 9.32% increase from fiscal 2025.
- Grace Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $730.00K, a 20.04% decline from fiscal 2024.
- Grace Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $913.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $105.00K 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $798.00K 10-K · filed 2026-06-18 | |||
| 2025-12-31 | $108.00K 10-Q · filed 2026-02-12 | $314.00K derived: sum of 2 quarters · filed 2026-02-12 | $616.00K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-09-30 | $206.00K 10-Q · filed 2026-02-12 | $508.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $302.00K 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $730.00K 10-K · filed 2026-06-18 | |||
| 2024-12-31 | $160.00K 10-Q · filed 2026-02-12 | $362.00K derived: sum of 2 quarters · filed 2026-02-12 | $600.00K derived: sum of 3 quarters · filed 2026-02-12 | |
| 2024-09-30 | $202.00K 10-Q · filed 2026-02-12 | $440.00K derived: sum of 2 quarters · filed 2026-02-12 | ||
| 2024-06-30 | $238.00K 10-Q · filed 2026-02-12 | |||
| 2024-03-31 | $913.00K 10-K · filed 2025-06-23 | |||
| 2023-12-31 | $326.00K 10-Q · filed 2025-02-13 | $606.00K derived: sum of 2 quarters · filed 2025-02-13 | $684.00K derived: sum of 3 quarters · filed 2025-02-13 | |
| 2023-09-30 | $280.00K 10-Q · filed 2025-02-13 | $358.00K derived: sum of 2 quarters · filed 2025-02-13 | ||
| 2023-06-30 | $78.00K 10-Q · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |